摘要
目的探讨HIV患者CD4+T淋巴细胞检测结果与抗病毒治疗效果。方法选择我院自2016年1月至2019年8月收治的339例HIV感染者作为研究对象,按患者是否接受综合抗病毒方案将其分为治疗组(258例)和未治疗组(81例),治疗前后分别对两组患者行CD4+T淋巴细胞检测,对比两组患者治疗前及3个月后的CD4+T淋巴细胞相关细胞因子表达水平(包含CD4,CD3/CD8)、病毒载量及病死率。结果治疗前,两组患者CD4,CD3/CD8水平对比均无显著差异(P> 0.05),治疗后,治疗组患者CD4,CD3/CD8水平均显著高于未治疗组,治疗组患者病毒载量、病死率均显著低于对照组,两组对比具有统计学意义(P <0.05)。结论通过CD4+T淋巴细胞检测结果不仅能判断HIV患者病情,还能评估其抗病毒治疗效果。
Objective To investigate the results of CD4+T lymphocyte detection and antiviral therapy in HIV patients. Methods A total of 339 HIV-infected patients admitted to our hospital from January 2016 to August 2019 were enrolled. The patients were divided into treatment group(258 cases) and untreated group according to whether they received comprehensive antiviral therapy. For example, CD4+T lymphocytes were detected in both groups before and after treatment, and CD4+T lymphocyte-associated cytokine expression levels(including CD4, CD3/CD8) were compared before treatment and three months after treatment. viral load and mortality. Results Before treatment, there was no significant difference in CD4 and CD3/CD8 levels between the two groups(P>0.05). After treatment, the CD4 and CD3/CD8 levels in the treatment group were significantly higher than those in the untreated group. The amount and mortality were significantly lower than the control group, and the two groups were statistically significant(P<0.05). Conclusion The results of CD4+T lymphocyte assay can not only judge the condition of HIV patients, but also evaluate the antiviral treatment effect.
作者
许海芬
XU Hai-fen(Pingle County Center for Disease Control and Prevention,Guilin 542407,China)
出处
《中国医药指南》
2020年第21期71-72,共2页
Guide of China Medicine
